NCT05074121View on ClinicalTrials.gov

NAC for Attenuation of COVID-19 Symptomatology

PHASE2UnknownINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

February 1, 2025

Conditions

Covid19COVID-19 PneumoniaCOVID-19 Respiratory InfectionCOVID-19 Lower Respiratory InfectionSARS-CoV2 InfectionSARS-CoV-2 Acute Respiratory DiseaseSARS-Associated Coronavirus as Cause of Disease Classified ElsewhereOxidative Stress

Interventions

DRUG

N-acetylcysteine

OTHER

Placebo

Trial Locations (1)

02149

Cambridge Health Alliance, Everett